Biodexa Pharmaceuticals (BDRX) Accounts Payables (2013 - 2025)

Biodexa Pharmaceuticals has disclosed Accounts Payables across 13 years of filings, most recently posting $3.4 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 23.4% year-over-year to $3.4 million; the TTM figure through Dec 2025 stood at $3.4 million (down 23.4% YoY), while the FY2025 annual figure was $3.4 million, down 23.76% from the prior year.
• Accounts Payables came in at $3.4 million for Q4 2025 at Biodexa Pharmaceuticals, up from $1.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.5 million in Q4 2024 to a low of $1.5 million in Q4 2021.
• Average Accounts Payables over 5 years is $2.3 million, with a median of $2.0 million recorded in 2024.
• Year-over-year, Accounts Payables slumped 43.41% in 2022 and jumped 192.22% in 2024.
• Over 5 years, Accounts Payables stood at $1.5 million in 2021, then rose by 15.3% to $1.7 million in 2022, then decreased by 9.32% to $1.5 million in 2023, then jumped by 192.22% to $4.5 million in 2024, then fell by 23.4% to $3.4 million in 2025.
• Per Business Quant data, the three most recent Accounts Payables figures were $3.4 million in Q4 2025, $1.9 million in Q2 2025, and $4.5 million in Q4 2024.